| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/22/2011 | US7910114 Methods of treating infectious diseases |
| 03/22/2011 | US7910113 Tolerizing agents |
| 03/22/2011 | US7910112 Feline vaccines against avian influenza |
| 03/22/2011 | US7910111 Inhibitors of N-ethylmaleimide sensitive factor |
| 03/22/2011 | US7910110 Bacteriophage-mediated immunisation against hepatitis |
| 03/22/2011 | US7910109 Major histocompatibility complex epitope for use in treatment and prevention of cell proliferative disorders; immunotherapy |
| 03/22/2011 | US7910108 Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| 03/22/2011 | US7910107 Antagonist antibodies against GDF-8 and uses in treatment of ALS and other GDF-8 associated disorders |
| 03/22/2011 | US7910106 Combinations of SAP depleting agents and anti-SAP antibodies |
| 03/22/2011 | US7910105 Methods for treating and preventing fibrosis |
| 03/22/2011 | US7910104 Modified anti-CD52 antibody |
| 03/22/2011 | US7910103 Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| 03/22/2011 | US7910102 Methods of using conjugated toxin peptide therapeutic agents |
| 03/22/2011 | US7910100 Antibodies directed to the mammalian EAG1 ion channel protein |
| 03/22/2011 | US7910099 Antibodies to VLA-1 |
| 03/22/2011 | US7910098 capable of binding to mouse Vascular endothelial cell growth factor (VEGF) and human VEGF; cancer, diabetes related diseases, edema, inflammation |
| 03/22/2011 | US7910097 Common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1) and uses thereof |
| 03/22/2011 | US7910096 Human neutralizing antibodies against hemolytic uremic syndrome |
| 03/22/2011 | US7910095 Using immunoglobulin specific to shiga-like toxin as therapeutic tool in treatment and prevention of enterohemorrhagic escherichia infection |
| 03/22/2011 | CA2480273C Ph-sensitive polymer |
| 03/22/2011 | CA2464713C A peptide-based fluorescence polarization assay for detection of antibodies to mycobacterium bovis |
| 03/22/2011 | CA2461380C Hepatitis c virus vaccine |
| 03/22/2011 | CA2412050C A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| 03/22/2011 | CA2308127C Agonist and antagonist peptides of carcinoembryonic antigen (cea) |
| 03/22/2011 | CA2240409C Mammalian cx3c chemokine genes |
| 03/22/2011 | CA2236159C Vp antigens of the jc virus |
| 03/22/2011 | CA2223013C Methods of raising antibodies against e.coli of the family cs4-cfa/1 |
| 03/17/2011 | WO2011032179A1 Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same |
| 03/17/2011 | WO2011032161A2 Vaccines directed to langerhans cells |
| 03/17/2011 | WO2011032148A1 Methods for treating psoriasis |
| 03/17/2011 | WO2011032119A1 Modulation of yeast-based immunotherapy products and responses |
| 03/17/2011 | WO2011032108A2 Formulation for room temperature stabilization of a live attenuated bacterial vaccine |
| 03/17/2011 | WO2011032085A1 Methods for treating irritable bowel syndrome (ibs) |
| 03/17/2011 | WO2011032003A1 Immunization to reduce neurotoxicity during treatment with cytolytic viruses |
| 03/17/2011 | WO2011031893A1 Protein matrix vaccines of improved immunogenicity |
| 03/17/2011 | WO2011031870A1 Extracellular targeted drug conjugates |
| 03/17/2011 | WO2011031850A1 New vaccine formulations comprising saponin-containing adjuvants |
| 03/17/2011 | WO2011031840A1 Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders |
| 03/17/2011 | WO2011031833A2 Human anti-cancer antibodies |
| 03/17/2011 | WO2011031720A1 Bispecific nanobodies as a therapeutic for alzheimer's disease |
| 03/17/2011 | WO2011031676A2 Depleting immunosuppressive monocytes within a mammal |
| 03/17/2011 | WO2011031657A1 Use of an anti-il6 antibody to decrease hepcidin in cancer patients |
| 03/17/2011 | WO2011031600A1 Use of il-33 antagonists to treat fibrotic disease |
| 03/17/2011 | WO2011031438A2 Porcine torque teno virus vaccines and diagnosis |
| 03/17/2011 | WO2011031317A2 Vaccine for control of trypanosoma cruzi infection and chagas disease |
| 03/17/2011 | WO2011031139A1 An ataq protein or a part thereof as a vaccine |
| 03/17/2011 | WO2011031125A1 Recombinant proteins that can be expressed in escherichia coli as active ingredients of vaccines against 2009 outbreak h1n1 influenza a, and production method thereof |
| 03/17/2011 | WO2011031063A2 Composition for preventing or treating metabolic disorders, containing the anti-4-1bb antibody |
| 03/17/2011 | WO2011030841A1 Medicament including antibody composition specifically bound to human cc chemokine receptor 4 (ccr4) |
| 03/17/2011 | WO2011030218A1 Combination vaccines against respiratory tract diseases |
| 03/17/2011 | WO2011030103A1 Screening method and therapy with agonists of ddah i |
| 03/17/2011 | WO2011029996A1 Use of vap-1 inhibitors for treating fibrotic conditions |
| 03/17/2011 | WO2011029870A1 Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| 03/17/2011 | WO2011029869A1 Hypoallergenic hybrid polypeptides for the treatment of allergy |
| 03/17/2011 | WO2011029823A1 Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
| 03/17/2011 | WO2011029607A1 S. aureus allergen |
| 03/17/2011 | WO2011029193A1 Method of treating cancer by inhibiting trim59 expression or activity |
| 03/17/2011 | WO2011029126A1 Methods and reagents for producing antibodies against autoantigens |
| 03/17/2011 | WO2011011688A3 DENDRITIC CELL VACCINES FOR ASPARAGINYL- β - HYDROXYLASE EXPRESSING TUMORS |
| 03/17/2011 | WO2010129670A3 Method for modulating angiogenesis using fibromodulin |
| 03/17/2011 | WO2010128338A3 Use of herpes simplex virus particles for the expression of antigens |
| 03/17/2011 | WO2010085588A8 Modulating angiogenesis |
| 03/17/2011 | WO2008102208A3 Inhibition of platelet aggregation |
| 03/17/2011 | US20110067121 Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications |
| 03/17/2011 | US20110066111 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 03/17/2011 | US20110066101 Non-invasive ocular drug delivery |
| 03/17/2011 | US20110065587 Epitope testing using soluble hla |
| 03/17/2011 | US20110065187 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 03/17/2011 | US20110065186 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 03/17/2011 | US20110065180 Ex-vivo priming for generating cytotoxic t lymphocytes specific for non-tumor antigens to treat autoimmune and allergic disease |
| 03/17/2011 | US20110065178 Dendritic cell potentiation |
| 03/17/2011 | US20110065174 Hepatitis c virus codon optimized non-structural ns3/4a fusion gene |
| 03/17/2011 | US20110065173 Vector |
| 03/17/2011 | US20110065146 Expression of HIV polypeptides and production of virus-like particles |
| 03/17/2011 | US20110065132 Identification of Actinobacillus actinomycetemcomitans Antigens for use in the Diagnosis, Treatment and Monitoring of Periodontal Diseases |
| 03/17/2011 | US20110065125 Controlled platelet activation to monitor therapy of adp antagonists |
| 03/17/2011 | US20110065122 Method for accessing microbial diversity |
| 03/17/2011 | US20110065091 Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and Diagnostics |
| 03/17/2011 | US20110064821 Encapsulation of biologically active agents |
| 03/17/2011 | US20110064819 Encapsulation of biologically active agents |
| 03/17/2011 | US20110064795 Therapeutic vaccine targeted against P-glycoprotein 170 for inhibiting multidrug resistance in the treatment of cancers |
| 03/17/2011 | US20110064775 Metallo-organic system for the encapsulation and release of compounds of interest, method for obtaining same and uses thereof |
| 03/17/2011 | US20110064772 Viral adjuvants |
| 03/17/2011 | US20110064770 Immunization of an Individual Against Carcinomas and the Preliminary Stages Thereof |
| 03/17/2011 | US20110064769 Vv promoter-driven overexpression of recombinant antigens |
| 03/17/2011 | US20110064768 Immunogenic Compositions |
| 03/17/2011 | US20110064767 Cdna construct of salmonidae alphavirus |
| 03/17/2011 | US20110064766 Attenuated Vaccine Against Fish Pathogen Francisella Sp. |
| 03/17/2011 | US20110064765 Pcv-2 vaccine |
| 03/17/2011 | US20110064764 Attenuated Live Triple G Protein Recombinant Rabies Virus Vaccine for Pre- and Post-Exposure Prophylaxis of Rabies |
| 03/17/2011 | US20110064763 Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein |
| 03/17/2011 | US20110064762 Protein a compositions and methods of use |
| 03/17/2011 | US20110064761 Novel sequences of brachyspira, immunogenic compositions, methods for preparation and use thereof |
| 03/17/2011 | US20110064760 Polypeptides comprising epitopes of hiv gp41 and methods of use |
| 03/17/2011 | US20110064759 Method for the Identification of Extracellular Domains of Epstein Barr Virus (EBV) Tumor-Associated Latent Membrane Proteins and for the Selection of Antibody Reagents Reactive Therewith |
| 03/17/2011 | US20110064758 Infectious clones of torque teno virus |
| 03/17/2011 | US20110064757 Nucleic acid molecules and polypeptides for immune modulation |
| 03/17/2011 | US20110064756 Novel sequences of brachyspira, immunogenic compounds, methods for preparation and use thereof |
| 03/17/2011 | US20110064755 Methods for producing block copolymer/amphiphilic particles |
| 03/17/2011 | US20110064754 Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines |